



KRYXANA® - it's not just living longer. It's living well.

• **NCCN recommended**

- National Comprehensive Cancer Network® (NCCN®) now recognizes ribociclib (KRYXANA®) + ET, a Category 1 preferred treatment option, for showing an OS BENEFIT in the 1L treatment setting in patients with HR+/HER2- mBC¹

• **ESMO-MCBS**

- Highest score of any CDK4/6 inhibitor in the 1st line²⁻⁵ (based on OS, PFS, and QoL) [KRYXANA® + ET in premenopausal patients & KRYXANA® + AI in postmenopausal patients]

- **As demonstrated in the phase III MONALEESA-2 trial, with a median OS of over 5 years in postmenopausal patients receiving KRYXANA® + AI. ESMO-MCBS scores based on the phase III MONALEESA-2 trial and the phase III MONALEESA-7 trial.**^{2,3,6}

Indications:⁷

KRYXANA® is indicated in combination with:

- an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopausal women, with HR+/HER2- aBC or mBC, as initial endocrine-based therapy; or
- fulvestrant for the treatment of postmenopausal women with HR+/HER2- aBC or mBC, as initial endocrine-based therapy or following disease progression on endocrine therapy



- ✓ **CONSISTENT OS** benefits in combination with AI in 1st line aBC HR+/HER2-⁶⁻¹⁵
Proven superior efficacy vs chemotherapy in aggressive disease patients.¹⁶
- ✓ **CONFIDENCE** in providing patients the only CDK4/6i in Category-1 recommended by NCCN 2023.¹
- ✓ **COMFORT** by improving and maintaining QoL for patient according to ESMO-MCBS.²⁻⁵
- ✓ **CARE** with the longest safety follow-up (6.5 years).¹³
- ✓ **CONVENIENT** once a day, one SKU for easy dose modifications.⁷

1L, first line; aBC, advanced breast cancer; AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinase 4 and 6 inhibitors; ESMO-MCBS, European Society for Medical Oncology Magnitude of Clinical Benefit Scale; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; mBC, metastatic breast cancer; NCCN, National Comprehensive Cancer Network; OS, overall survival; PFS, progression-free survival; QoL, quality of life; SKU, stock-keeping unit.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Published June 21, 2022. Accessed July 29, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 2. ESMO MCBS scorecard 158 1. European Society for Medical Oncology. Accessed November 10, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1>. 3. ESMO MCBS scorecard 9 1. European Society for Medical Oncology. Accessed November 10, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1>. 4. ESMO MCBS scorecard 159 1. European Society for Medical Oncology. Accessed November 10, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-159-1>. 5. ESMO MCBS scorecard 7 1. European Society for Medical Oncology. Accessed November 10, 2022. <https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-7-1>. 6. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. *N Engl J Med*. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663. 7. KRYXANA® Malaysian Prescribing Information dated Feb 2022. 8. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. *N Engl J Med*. 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709. 9. Lu YS, Im SA, Colleoni M, et al. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. *Clin Cancer Res*. 2022;28(5):851-859. doi:10.1158/1078-0432.CCR-21-3032. 10. Im S-A, Lu Y-S, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. *N Engl J Med*. 2019;381(4):307-316. doi:10.1056/NEJMoa1903765. 11. Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol*. 2018;19(7):904-915. doi:10.1016/S1470-2045(18)30292-4. 12. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. *J Clin Oncol*. 2018;36(24):2465-2472. doi:10.1200/JCO.2018.78.9909. 13. Neven P, Fasching PA, Chia S, et al. Updated overall survival results from the first-line population in the phase III MONALEESA-3 trial of postmenopausal patients with HR+/HER2- advanced breast cancer treated with ribociclib + fulvestrant. Presented at: ESMO Breast Cancer 2022; May 3-5, 2022; Berlin, Germany. 14. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. *Ann Oncol*. 2021;32(8):1015-1024. doi:10.1016/j.annonc.2021.05.353. 15. Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. *N Engl J Med*. 2020;382(6):514-524. doi:10.1056/NEJMoa1911449. 16. Lu Y-S, Mahidin EIBM, Azim H, et al. Primary results from the randomized phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2- advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy. Presented at: San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX.

For Healthcare Professionals Only



Novartis Corporation (Malaysia) Sdn Bhd 197101000541
Level 18, Imazium, No. 8, Jalan SS21/37 Damansara Uptown
47400 Petaling Jaya, Selangor Darul Ehsan
Tel: +603 7682 7777 Fax: +603 7682 7000
www.novartis.com.my

KRYXANA
Product Information



KRY.5Cad01/MY2306082428